Sugi Predict

Sugi Predict / Compounds / SCHEMBL585492

SCHEMBL585492

SCHEMBL585492

COc1cc(Cl)ccc1Br

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TRPV4 Q9HBA0 1/20 0.50
▸ AMY1A P0DUB6 4/20 0.46
▸ MAPT P10636 2/20 0.46
▸ NPC1 O15118 2/20 0.46
▸ HSP90AA1 P07900 1/20 0.44
▸ HSP90AB1 P08238 1/20 0.44
▸ HTR2A P28223 1/20 0.43
▸ ALDH1A1 P00352 4/20 0.42
▸ LMNA P02545 1/20 0.42
▸ KDM4E B2RXH2 1/20 0.41
▸ MEN1 O00255 1/20 0.41
▸ KMT2A Q03164 1/20 0.41
▸ HPGD P15428 1/20 0.40
▸ TSHR P16473 1/20 0.40
▸ STAT3 P40763 1/20 0.40
▸ RAB9A P51151 1/20 0.40
▸ SMN1; SMN2 Q16637 1/20 0.40
▸ POLB P06746 1/20 0.40
▸ L3MBTL1 Q9Y468 1/20 0.40
▸ GRM4 Q14833 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29359707 1.00 TRPV4 (0.50) TRPV4AMY1AMAPTNPC1HSP90AA1
Magnesium SCHEMBL30697198 0.98 TRPV4 (0.48) TRPV4AMY1AMAPTNPC1HSP90AA1
SCHEMBL30259322 0.85 TRPV4 (0.38) TRPV4AMY1AMAPTNPC1HSP90AA1
SCHEMBL29958505 0.82 ALDH1A1 (0.52) TRPV4AMY1AMAPTNPC1HTR2A
SCHEMBL929274 0.82 ALDH1A1 (0.52) TRPV4AMY1AMAPTNPC1HTR2A
SCHEMBL16282203 0.80 CRHR1 (0.44) TRPV4AMY1AMAPTNPC1HSP90AA1
SCHEMBL18000003 0.80 CRHR1 (0.44) TRPV4AMY1AMAPTNPC1HSP90AA1
SCHEMBL20526464 0.80 ALDH1A1 (0.50) TRPV4AMY1AMAPTNPC1HTR2A
SCHEMBL2127233 0.78 TRPV4 (0.55) TRPV4MAPTALDH1A1LMNAMEN1
SCHEMBL29636402 0.78 TRPV4 (0.55) TRPV4MAPTALDH1A1LMNAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 273 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3981762-B1 NITROGEN-CONTAINING COMPOUND, ELECTRONIC ELEMENT, AND ELECTRONIC DEVICE SHAANXI LIGHTE OPTOELECTRONICS MAT CO LTD (CN) 2025-10-15 — — EP disclosed
US-20250214977-A1 STAT6 INHIBITORS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2025-07-03 — — US disclosed
WO-2025137483-A1 RHO-ASSOCIATED PROTEIN KINASE INHIBITORS ELI LILLY AND COMPANY (US) 2025-06-26 — — WO disclosed
WO-2025125666-A1 SUBSTITUTED IMIDAZOLES AS INHIBITORS OF NAV1.8 Grünenthal GmbH (DE) 2025-06-19 — — WO disclosed
US-20250136611-A1 HETEROBIFUNCTIONAL COMPOUNDS AND METHODS OF TREATING DISEASE HALDA THERAPEUTICS OPCO, INC. 2025-05-01 — — US disclosed
WO-2025085738-A1 HETEROBIFUNCTIONAL COMPOUNDS AND METHODS OF TREATING DISEASE HALDA THERAPEUTICS OPCO, INC. (US) 2025-04-24 — — WO disclosed
WO-2025020191-A1 STEROID COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF 珂阑(上海)医药科技有限公司 2025-01-30 — — WO disclosed
WO-2025021193-A1 STEROID COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF 珂阑(上海)医药科技有限公司 2025-01-30 — — WO disclosed
CN-119080647-A Preparation method of 4-chloro-2-methoxy benzenesulfonyl chloride 南京药石科技股份有限公司 2024-12-06 — — CN disclosed
CN-119080647-A Preparation method of 4-chloro-2-methoxy benzenesulfonyl chloride 南京药石科技股份有限公司 2024-12-06 — — CN disclosed
EP-1826201-A1 Substituted phenylpiperidine derivatives as melanocortin-4 receptor modulators Santhera Pharmaceuticals (Schweiz) AG (CH) 2007-08-29 — — EP disclosed
US-20060276507-A1 Hydroxamate sulfonamides as cd23 shedding inhibitors CELLTECH R&D LIMITED (GB) 2006-12-07 — — US disclosed
EP-1648868-B1 HYDROXAMATE SULFONAMIDES AS CD23 SHEDDING INHIBITORS CELLTECH R&D LTD (GB) 2006-11-15 — — EP disclosed
CN-1829521-A Hydrolysis resistant boron-containing therapeutics and methods of use ANACOR PHARMACEUTICALS INC (US) 2006-09-06 — — CN disclosed
EP-1648868-A1 HYDROXAMATE SULFONAMIDES AS CD23 SHEDDING INHIBITORS Celltech R & D Limited (GB) 2006-04-26 — — EP disclosed
EP-1638578-A2 HYDROLYTICALLY-RESISTANT BORON-CONTAINING THERAPEUTICS AND METHODS OF USE Anacor Pharmaceuticals, Inc. (US) 2006-03-29 — — EP disclosed
WO-2005013892-A9 HYDROLYTICALLY-RESISTANT BORON-CONTAINING THERAPEUTICS AND METHODS OF USE ANACOR PHARMACEUTICALS INC (US) 2005-04-14 — — WO disclosed
US-20050054644-A1 Hydrolytically-resistant boron-containing therapeutics and methods of use ANACOR PHARMACEUTICALS, LLC 2005-03-10 — — US disclosed
WO-2005013892-A2 HYDROLYTICALLY-RESISTANT BORON-CONTAINING THERAPEUTICS AND METHODS OF USE ANACOR PHARMACEUTICALS, INC. (US) 2005-02-17 — — WO disclosed
WO-2004113298-A1 HYDROXAMATE SULFONAMIDES AS CD23 SHEDDING INHIBITORS CELLTECH R & D LIMITED (GB) 2004-12-29 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250136611-A1 HETEROBIFUNCTIONAL COMPOUNDS AND METHODS OF TREATING DISEASE VHL, BRCA1, TP53 TRPV4 2705/4885AMY1A 2822/4885MAPT 2496/4885
US-20060276507-A1 Hydroxamate sulfonamides as cd23 shedding inhibitors CD2, CD22, NEU3 TRPV4 290/4885AMY1A 4331/4885MAPT 4819/4885
US-20250214977-A1 STAT6 INHIBITORS AND USES THEREOF STAT6, STAT5B, STAT5A TRPV4 1684/4885AMY1A 4673/4885MAPT 3335/4885
US-20050054644-A1 Hydrolytically-resistant boron-containing therapeutics and methods of use BTD, GAA, GBA3 TRPV4 4716/4885AMY1A 522/4885MAPT 3790/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.